EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib

Yoshiya Tanaka iD, Tsutomu Takeuchi, Hernan Valdez, Mark Collinge, Samuel H Zwillich, Shigeyuki Toyoizumi, Kenneth Kwok, Tomohiro Hirose iD

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Yoshiya Tanaka und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Piperidines, Pyrimidines, Herpes Zoster. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme.

Methods

Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months.

Results

Median ALCs were generally stable over 75 months of treatment. Transient numerical increases from baseline in median LSCs were observed at Month 3; LSCs were generally lower than baseline for Months 36–75. SIE/HZ incidence rates were higher in patients with ALC <0.5 × 103 cells/mm3 versus those with ALC ≥0.5 × 103 cells/mm3 during tofacitinib treatment. Baseline LSCs were similar in patients with/without SIEs or HZ events.

Conclusions

SIE/HZ risk was highest in patients with ALC <0.5 × 103 cells/mm3, supporting this threshold as clinically relevant for defining increased SIE/HZ risk in Japanese patients with rheumatoid arthritis receiving tofacitinib. However, SIEs and HZ events did not necessarily occur simultaneously with confirmed lymphopenia, preventing conclusions on possible causal relationships being drawn.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPiperidinesPyrimidinesHerpes ZosterHumansMaleFemaleMiddle AgedLymphocyte CountAgedJapanPyrrolesAdultAntirheumatic AgentsIncidenceInfectionsProtein Kinase InhibitorsEast Asian People

Stichwörter der Autor:innen

InfectionsJapanlymphocytesrheumatoid arthritistofacitinib

Substanzen

tofacitinibPiperidinesPyrimidinesPyrrolesAntirheumatic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Keio University, Tokyo, Japan.
  • Pfizer Inc, New York, NY, USA.
  • Pfizer Inc, Groton, CT, USA.
  • Pfizer R&D Japan G.K., Tokyo, Japan.
  • Pfizer Japan Inc, Tokyo, Japan.

ORCID-Profile: Yoshiya Tanaka, Tomohiro Hirose

Zitieren

APA

Tanaka, Y., Takeuchi, T., Valdez, H., Collinge, M., Zwillich, S. H., Toyoizumi, S., Kwok, K., & Hirose, T. (2024). Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib. Modern Rheumatology. https://doi.org/10.1093/mr/roae030

Vancouver

Tanaka Y, Takeuchi T, Valdez H, Collinge M, Zwillich SH, Toyoizumi S, et al. Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib. Modern Rheumatology. 2024. doi:10.1093/mr/roae030

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Yoshiya and Takeuchi, Tsutomu and Valdez, Hernan and Collinge, Mark and Zwillich, Samuel H and Toyoizumi, Shigeyuki and Kwok, Kenneth and Hirose, Tomohiro},
  title = {Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae030}
}
Kostenlos starten →